Neuropeptide Y (NPY) intranasal delivery alleviates Machado–Joseph disease
Abstract Machado–Joseph disease (MJD) is the most common dominantly-inherited ataxia worldwide with no effective treatment to prevent, stop or alleviate its progression. Neuropeptide Y (NPY) is a neuroprotective agent widely expressed in the mammalian brain. Our previous work showed that NPY overexp...
Enregistré dans:
Auteurs principaux: | Joana Duarte-Neves, Cláudia Cavadas, Luís Pereira de Almeida |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/5e8895de18654bcbb26bcfb30a822f35 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Caloric restriction blocks neuropathology and motor deficits in Machado–Joseph disease mouse models through SIRT1 pathway
par: Janete Cunha-Santos, et autres
Publié: (2016) -
Ataxia espinocerebelosa tipo 3 (enfermedad de Machado-Joseph) y vareniclina
par: Young,Pablo, et autres
Publié: (2015) -
Diagnóstico de Ataxia Espinocerebelosa tipo 3 (Enfermedad de Machado-Joseph) en Chile
par: Miranda C.,Marcelo
Publié: (2015) -
Intranasal Delivery of Nerve Growth Factor in Neurodegenerative Diseases and Neurotrauma
par: Luigi Manni, et autres
Publié: (2021) -
Intranasal Delivery of miR-155-5p Antagomir Alleviates Acute Seizures Likely by Inhibiting Hippocampal Inflammation
par: Zhou X, et autres
Publié: (2020)